The following table displays underlying oil and natural gas sales volumes and average received wellhead prices attributable to the current and prior month net profits interest calculations.
Underlying Sales Volumes | Average Price | ||||||||||||||||||||
Oil | Natural Gas | Oil | Natural Gas | ||||||||||||||||||
Bbls | Bbls/D | Mcf | Mcf/D | (per Bbl) | (per Mcf) | ||||||||||||||||
Current Month | 58,110 | 1,875 | 400,200 | 13,340 | $ | 62.82 | $ | 2.58 | |||||||||||||
Prior Month | 55,566 | 1,852 | 394,953 | 12,740 | $ | 62.81 | $ | 2.50 | |||||||||||||
Oil cash receipts for the properties underlying the Trust totaled
Natural gas cash receipts increased slightly from the prior distribution period to
Total direct operating expenses, including lease operating expenses, production and ad valorem taxes, and gathering and transportation expenses, were
About
Forward-Looking Statements and Cautionary Statements
This press release contains statements that are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release, other than statements of historical facts, are “forward-looking statements” for purposes of these provisions. These forward-looking statements include the amount and date of any anticipated distribution to unitholders and expected expenses, including capital expenditures. The anticipated distribution is based, in large part, on the amount of cash received or expected to be received by the Trust from
View source version on businesswire.com: https://www.businesswire.com/news/home/20180821005211/en/
Source:
CytoSorbents Awarded up to $3M in SBIR Phase IIB Bridge Funding by NIH/NHLBI to Accelerate U.S. Approval and Commercialization of the HemoDefend™ Blood Transfusion Filter
SEC: Bay Area venture capitalist agrees to settle charges in allegedly ‘fraudulent scheme’
More Articles